Clinical Trial Update: Neratinib in Combination With Ruxolitinib in Patients With mTNBC [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial is investigating the combination of neratinib and ruxolitinib for metastatic triple-negative breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Neratinib (Nerlynx) (neratinib)
• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: Baylor Research Institute | Conditions: Metastatic Triple-Negative Breast Carcinoma, Breast Cancer | EARLY_Phase 1 | Status: RECRUITING